* Acer Therapeutics Inc ACER.OQ reported a quarterly
adjusted
loss of 17 cents per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 57 cents per share.
* Reported revenue was zero; analysts expected zero.
* Acer Therapeutics Inc's reported EPS for the quarter was a
loss
of 17 cents.
* The mean earnings estimate of analysts had fallen by
about 9.6%
in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Acer Therapeutics Inc shares had risen by 16.7% this
quarter and
lost 35.5% so far this year.
* The company reported a quarterly loss of $2.67 million.
* Wall Street's median 12-month price target for Acer
Therapeutics
Inc is $10.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 15
at 09:06 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.57 -0.17 Beat
Mar. 31 2022 -0.41 -0.64 Missed
Dec. 31 2021 -0.01 -0.31 Missed
Sep. 30 2021 -0.28 -0.23 Beat